İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

sanofi pasteur - haemophilus influenzae type b, conjugate with tetanus protein - pdr+solv for soln for inj - 10mcg/0.5m microgram/ml - hemophilus influenzae b vaccines

Filipinler - İngilizce - FDA (Food And Drug Administration)

n/a; importer: sanofi pasteur, inc.; distributor: zuellig pharma corporation - diphtheria, tetanus, pertussis (acellular component), hepatitis b, poliomyelitis (inactivated) and haemophilus influenzae type b conjugate vaccine (adsorbed) - suspension for injection (im) - formulation: each dose (0.5 ml) contains: diphtheria toxoid' tetanus toxoid ' bordetella pertussis antigen pertussis toxoid' filamentous hemagglutinin' poliovirus (inactivated)2.3 type i (mahoney) strain nlt 20 iu nlt 40 iu hepatitis b surface antigen haemophilus influenzae type b polysaccharide phosphate) 10 mcg (polyribosylribitol 12 mcg conjugate to tetanus protein 22-36 mcg 25 mcg 25 mcg 40 d antigen units type ii (mef-1) strain" type iii (saukett) strain1 8 d antigen units 32 d antigen units 'adsorbed on aluminium hydroxide, hydrated (al(oh)3) 2produced in yeast cells (saccharomyces cerevisiae) by recombinant dna technology 3adsorbed on aluminium phosphate (aipo4) *propagated in vero cells

ABD - İngilizce - NLM (National Library of Medicine)

sanofi pasteur inc. - haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (unii: flv5i5w26r) (haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen - unii:flv5i5w26r) - haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen 10 ug in 0.5 ml - acthib® is a vaccine indicated for the prevention of invasive disease caused by haemophilus influenzae (h. influenzae) type b. acthib is approved for use in children 2 months through 5 years of age. severe allergic reaction (e.g., anaphylaxis) after a previous dose of any h. influenzae type b or tetanus toxoid-containing vaccine or any component of the vaccine is a contraindication to administration of acthib vaccine [see description (11)] . acthib is not approved for use in individuals 6 years of age and older. no human or animal data are available to assess vaccine-associated risks in pregnancy. acthib is not approved for use in individuals 6 years of age and older. human or animal data are not available to assess the impact of acthib on milk production, its presence in breast milk, or its effects on the breastfed infant. safety and effectiveness of acthib have not been established in infants below the age of 6 weeks and children and adolescents 6 years of age and older [see dosage and administration (2.1)] .

Avrupa Birliği - İngilizce - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin), hepatitis b surface antigen, poliovirus (inactivated) (type-1 (mahoney strain), type-2 (mef-1 strain), type-3 (saukett strain)), haemophilus influenzae type b polysaccharide - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaccines - infanrix hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and disease caused by haemophilus influenzae type-b.

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - haemophilus influenzae type b polysaccharide; conjugate of haemophilus influenzae type b capsular polysaccharide (prp) and tetanus toxoid - powder and solvent for solution for injection - 0.5 millilitre(s) - hemophilus influenzae b, combinations with toxoids

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - conjugate of haemophilus influenzae type b capsular polysaccharide (polyribosylribitol phosphate) and tetanus; conjugate of neisseria meningitides c capsular polysaccharide and tetanus toxoid (mean tt/ps ratio :1) - powder and solvent for solution for injection - 0.5 millilitre(s) - hemophilus influenzae b, combinations with meningococcus c, conjugated

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - diphtheria toxoid, adsorbed 30 lf u equivalent to not less than 20 iu; haemophilus influenzae type b polysaccharide 12ug ((polyribosylribitol phosphate) conjugated to tetanus protein (22-36 mcg)); hepatitis b virus surface antigen 10ug; pertussis filamentous haemagglutinin 25ug (adsorbed); pertussis toxoid, adsorbed 25ug; polio virus type 1 40 dagu (mahoney); polio virus type 2 8 dagu (mef-1); polio virus type 3 32 dagu (saukett); tetanus toxoid, adsorbed 10 lf u equivalent to not less than 40 iu - suspension for injection - active: diphtheria toxoid, adsorbed 30 lf u equivalent to not less than 20 iu haemophilus influenzae type b polysaccharide 12ug ((polyribosylribitol phosphate) conjugated to tetanus protein (22-36 mcg)) hepatitis b virus surface antigen 10ug pertussis filamentous haemagglutinin 25ug (adsorbed) pertussis toxoid, adsorbed 25ug polio virus type 1 40 dagu (mahoney) polio virus type 2 8 dagu (mef-1) polio virus type 3 32 dagu (saukett) tetanus toxoid, adsorbed 10 lf u equivalent to not less than 40 iu excipient: aluminium hydroxide amino acids dibasic sodium phosphate monobasic potassium phosphate sucrose trometamol water for injection - hexaxim is indicated for vaccination of infants from six weeks of age against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and invasive infections caused by haemophilus influenzae type b. use of this vaccine should be in accordance with the national recommendation as per the current immunisation handbook.

Filipinler - İngilizce - FDA (Food And Drug Administration)

n/a; importer: medical vaccines online deliveries; distributor: medical vaccines online deliveries - diphtheria, tetanus, pertussis, hepatitis b (rdna) and haemophilus influenzae type b conjugate vaccine (adsorbed) - suspension for injection (im) - formulation: each dose (0.5 ml) contains: diptheria toxoid.............<25 lfl> 30 i.u.) tetanus toxoid.............> 2.5 lf> 40 i.u.) . bordetella pertussis (whole cell)............< 16 ou (>4 1.u.) . hepatitis b (rdna)....................10 mcg haemophilus influenzae congugate vaccine............ > 10 mcg

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

gsk vaccines s.r.l. - meningococcal group c oligosaccharide; corynebacterium diphtheriae crm197 protein - suspension for injection in pre-filled syringe - 10 - meningococcal vaccines; other meningococcal polyvalent purified polysaccharides antigen - meningococcal vaccines - active immunisation of children from 2 months of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis group c.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tetanus toxoid, quantity: 20 microgram/ml; meningococcal polysaccharide group c, quantity: 20 microgram/ml - injection, suspension - excipient ingredients: sodium chloride; water for injections; aluminium hydroxide hydrate - neisvac-c vaccine is indicated for active immunisation of children from 8 weeks of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis serogroup c.